Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern?

Andrew Teo,Hao Dong Tan,Thomas Loy,Po Ying Chia,Caroline Lin Lin Chua

DOI: https://doi.org/10.1371/journal.ppat.1011223

IF: 7.464

2023-03-31

PLoS Pathogens

Abstract:DENV has a positive-sense RNA genome that encodes for seven nonstructural proteins and three structural glycoproteins (the capsid shell, envelope (E) and premembrane (prM) proteins) that are responsible for virus attachment, entry, and maturation [6]. Although all serotypes are closely related, a significant degree of sequence diversity exists [4]. As a result, a subset of IgGs that target viral proteins from one serotype may cross-react with those from other serotypes and exhibit poor neutralising function. For instance, the noninfectious immature virions have a "spiky" appearance, because of higher surface exposure of immunodominant epitopes (pr fragment of the prM proteins and fusion loop in the E proteins) [7]. These epitopes are recognised by low levels of cross-reactive IgGs, promoting entry into FcγR-bearing cells that lead to infectious virus maturation and immune suppression that favours viral replication [4,8,9]. Additionally, decreased neutralising antibody concentrations due to waning immunity may also predispose to ADE. Decay in maternal anti-DENV antibody titres, estimated at 1:320 titres, protected against symptomatic dengue, whereas individuals with anti-DENV antibody titres between 1:21 and 1:80 were more susceptible to severe dengue [2,3]. A mouse model of dengue was used to delineate ADE pathways, and in pups born to DENV-1 immune dams, older pups (>3 weeks old) were more likely to succumb to vascular leakage and death compared to their younger counterparts (2 weeks old) when challenged with DENV-2. In the same study, sera from older pups displayed lower neutralising activities, and their sera demonstrated ADE-mediated increased viremia in vitro [11]. Similarly, in a nonhuman primate model, passive transfer of monoclonal anti-DENV IgG 1A5 at lower concentration (0.22 to 0.67mg/kg) demonstrated increased viremia titre when challenged with DENV-4 [12]. Overall, these observations reinforce the hypothesis that waning immunity may contribute to ADE-mediated outcomes (Fig 1A). Given that FcγRs mediate DENV immune complex uptake, their phenotypic and genetic expression on immune cells may also determine the risk of ADE. FcγRs are surface receptors on lymphoid and myeloid cells, with a unique distribution on each cell type. They can be classified as activating or inhibitory receptors, depending on their intracellular domains. In vitro studies reported that FcγRIIa (CD32a) and FcγRI (CD64) mediate ADE in primary monocytes [13], while FcγRIIa and FcγRIIIa (CD16a) were shown to promote ADE in U937 promonocytic cell line [14]. In contrast, interaction between DENV immune complexes and FcγRIIb, an inhibitory FcγR, prevents phagocytosis and reduces the likelihood ADE in monocytes [15]. In populational studies, genetic polymorphism in FcγRIIa results in a single amino acid alteration (arginine instead of histidine at position 131) and is protective against dengue haemorrhagic fever. This is presumably due to increased binding affinity of their FcγRIIa for IgGs, which subsequently accelerates DENV elimination [16,17]. However, due to limited studies, the association between genetic polymorphism in FcγR genes and the risk of ADE is still not well understood. Lastly, immune cell populations and subpopulations are known to express different levels and types of FcγR, which can change during an infection. For example, FcγRIIa expression can be down-regulated in classical monocytes and up-regulated in intermediate and nonclassical monocytes in dengue [18,19]. Whether or not these changes influence the risk of ADE remains to be determined.

microbiology,virology,parasitology